Bosco I, Teh A
Department of Medicine, University Hospital, University of Malaya, Kuala Lumpur.
Leukemia. 1995 Jun;9(6):951-4.
Reports on the outcome of treatment in ALL in Asian (non-Caucasian) adults have been few, and published results compare very unfavourably with results of treatment from 'Western' centres. Seventy-four newly diagnosed Malaysian patients with ALL between the ages of 15 and 69 were treated from 1986 to 1990. The clinical features and prognostic factors were similar to those reported in 'Western' series. The chemotherapy protocol utilized was adapted from the one used by Hoelzer et al in the multicentre German study. The complete remission rate was 73%. The probability of continuous complete remission at 5 years was 29% with a median duration of remission of 15 months. This compares with Hoelzer's initial results of 77% CR rate and 35% CCR at 5 years. Patients with an initial white cell count of less than 30 x 10(9)/l at presentation were found to have a significantly better disease-free survival than those with a count of more than 30 x 10(9)/l (35 vs 22%, P = 0.026, univariate analysis). There was no difference in leukaemia-free survival according to age, sex, ethnic group, or immunophenotype. These results show that the use of moderately intensive chemotherapy protocols in Asian (non-Caucasian) patients achieves similar results to those used in Caucasians. We also showed that the difficulties in 'curing' approximately 70% of adult patient with ALL are universal.
关于亚洲(非白种人)成年急性淋巴细胞白血病(ALL)患者治疗结果的报告很少,而且已发表的结果与“西方”中心的治疗结果相比非常不利。1986年至1990年期间,对74例年龄在15至69岁之间新诊断的马来西亚ALL患者进行了治疗。其临床特征和预后因素与“西方”系列报道的相似。所采用的化疗方案是根据霍泽尔等人在德国多中心研究中使用的方案改编的。完全缓解率为73%。5年持续完全缓解的概率为29%,缓解期中位数为15个月。相比之下,霍泽尔最初的结果是完全缓解率为77%,5年持续完全缓解率为35%。发现初诊时白细胞计数低于30×10⁹/L的患者无病生存率明显高于白细胞计数高于30×10⁹/L的患者(35%对22%,单因素分析,P = 0.026)。根据年龄、性别、种族或免疫表型,无白血病生存率没有差异。这些结果表明,在亚洲(非白种人)患者中使用中等强度的化疗方案可取得与白种人相似的结果。我们还表明,“治愈”大约70%的成年ALL患者所面临的困难是普遍存在的。